MedCity News September 15, 2024
Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.
Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for cancer. Each one shaves a patient’s dosing time down to minutes.
The cancer drug approval went to Tecentriq Hybreza, a subcutaneously injectable version of the Roche immunotherapy Tecentriq. Dosing is a seven-minute injection in the thigh every three weeks. By comparison, IV infusion of Tecentriq takes about 30...
Today's Sponsors
Today's Sponsor